Iron Status in Infants in Ethiopia.

Status Not yet recruiting

Clinical Trial Summary

To assess the impact of soil iron intake from teff flour on iron status in infants in Debre Zeit, Ethiopia.

Clinical Trial Description

Rationale: Teff (Eragrostis Teff), a major staple crop in several areas of Ethiopia, is of special relevance to Fe biofortifcation as it provides the population with a regular high consumption of contaminant soil Fe due to the traditional threshing procedure under the hooves of the cattle. The bioavailability of soil Fe, and hence its contribution to Fe requirements, is unknown. Data on the bioavailability of soil Fe would clarify to what extent the soil Fe can be considered as a source of absorbable Fe. This information is important in order to establish dietary advice and is essential for the development of iron biofortification (and fortification) policies related to Fe nutrition in Ethiopia.

Objective: The overall objective of the project is to generate data to target and tailor biofortification approaches in Ethiopia by an intervention trial assessing the impact of soil Fe intake from teff consumption on Fe status.

Study design: The intervention trial will be a 7 months partially blinded, randomized control trial (RCT) with the following three arms: control-group consuming injera based on traditionally threshed teff (average Fe content 50 mg/100g flour), 2) intervention group consuming injera based on lab-threshed teff (average Fe content 6.65 mg/100g flour), 3) positive control group consuming the lab-threshed teff together with ferrous sulphate iron drops (additional Fe from the drops = 6 mg).

Study population: 315 children between 18-36 months of age living in Debre Zeit and surrounding areas will be enrolled.

Main study parameters/endpoints: The impact of soil Fe in teff on Fe status will be assessed by measuring the Fe status, prevalence of Fe deficiency and Fe deficiency anemia at baseline, midpoint and endpoint. To assess Fe status, Hemoglobin (Hb), Plasma Ferritin (PF), Soluble Transferrin Receptor (sTfR), C- Reactive Protein(CRP) and Alpha 1B glycoprotein (AGP) will be determined. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03355287
Study type	Interventional
Source	Swiss Federal Institute of Technology
Contact	Colin Cercamondi, PhD
Phone	+41 44 632 86 34
Email	colin.cercamondi@hest.ethz.ch
Status	Not yet recruiting
Phase	N/A
Start date	November 2018
Completion date	August 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06027801` - Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity	N/A
Completed	`NCT02282553` - Gastric Capsule Examination for Iron Deficiency Anaemia	N/A
Recruiting	`NCT05217836` - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting	`NCT04913649` - Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients	Phase 4
Completed	`NCT02176759` - Iron Absorption From Rice Fortified With Ferric Pyrophosphate	N/A
Completed	`NCT01438645` - ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy	N/A
Completed	`NCT01307007` - Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding	Phase 2
Completed	`NCT00982007` - Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)	Phase 3
Completed	`NCT00198848` - Iron Supplementation Among Adolescent Girls in India	N/A
Completed	`NCT01166451` - The Anemia Control Program: High or Low Iron Supplementation	N/A
Recruiting	`NCT03893045` - A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects	Phase 3
Recruiting	`NCT03817957` - Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency	Phase 3
Completed	`NCT03819530` - Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study	N/A
Completed	`NCT03618914` - Anemia and Inflammation
Completed	`NCT03940430` - Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students	Phase 2/Phase 3
Withdrawn	`NCT03873584` - Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
Enrolling by invitation	`NCT03897673` - Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas	N/A
Active, not recruiting	`NCT04778072` - A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects	N/A
Completed	`NCT03237065` - Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia	Phase 3
Completed	`NCT05153278` - IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.